These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9408020)

  • 21. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants.
    Cadroy Y; Sié P; Alhenc-Gelas M; Aiach M
    Thromb Haemost; 1995 Apr; 73(4):734-5. PubMed ID: 7495093
    [No Abstract]   [Full Text] [Related]  

  • 22. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature.
    Zürcher M; Sulzer I; Barizzi G; Lämmle B; Alberio L
    Thromb Haemost; 2008 Feb; 99(2):416-26. PubMed ID: 18278194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
    Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
    Kabukcu S; Keskin N; Keskin A; Atalay E
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Blood plasma resistance to activated protein C as a risk factor of disseminated intravascular coagulation in acute-poisoned patients].
    Barańska M; Kur B; Prazanowski M; Lutz W
    Pol Merkur Lekarski; 2004 Oct; 17(100):357-60. PubMed ID: 15690701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2.
    Lambropoulos AF; Foka Z; Makris M; Daly M; Kotsis A; Makris PE
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):485-9. PubMed ID: 9491265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
    Dahlbäck B; Zöller B; Hillarp A
    Haemostasis; 1996 Oct; 26 Suppl 4():301-14. PubMed ID: 8979136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K; Dahlbäck B; Nicolaes GA
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma.
    Kapiotis S; Quehenberger P; Jilma B; Handler S; Pabinger-Fasching I; Mannhalter C; Speiser W
    Am J Clin Pathol; 1996 Nov; 106(5):588-93. PubMed ID: 8929467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
    Ts'ao C; Neofotistos D; Oropeza M; Vahabinejad S; Finn WG
    Am J Hematol; 1997 Mar; 54(3):214-8. PubMed ID: 9067500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraindividual consistency of the activated protein C resistance phenotype.
    Tosetto A; Simioni M; Madeo D; Rodeghiero F
    Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APC resistance and factor V Leiden (FV:Q506) mutation in patients with ischemic cerebral events. Vienna Thrombophilia in Stroke Study Group (VITISS).
    Halbmayer WM; Haushofer A; Angerer V; Finsterer J; Fischer M
    Blood Coagul Fibrinolysis; 1997 Sep; 8(6):361-4. PubMed ID: 9351526
    [No Abstract]   [Full Text] [Related]  

  • 34. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
    Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
    Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of phenotype resistance to activated protein C (APC resistance)].
    Hudecek J; Ivanková J; Dobrotová M; Hybenová J; Pullmann R; Kubisz P
    Vnitr Lek; 1999 Dec; 45(12):723-8. PubMed ID: 10951849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heightened thrombin generation in individuals with resistance to activated protein C.
    Martinelli I; Bottasso B; Duca F; Faioni E; Mannucci PM
    Thromb Haemost; 1996 May; 75(5):703-5. PubMed ID: 8725708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
    Villoutreix BO; Dahlbäck B
    Protein Sci; 1998 Jun; 7(6):1317-25. PubMed ID: 9655335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Instrument effect on the activated protein C resistance plasma assay performed by a commercial kit.
    De Stefano V; Paciaroni K; Mastrangelo S; Rutella S; Bizzi B; Leone G
    Thromb Haemost; 1996 May; 75(5):752-6. PubMed ID: 8725718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detecting APC-resistant factor V: a functional method without plasma dilution.
    Rylatt DB; Hohnen-Behrens C; Pilgrim RL; Dickeson LE; Neal M; Exner T
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):359-66. PubMed ID: 10493217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.